Recent Posts
- Breakthrough Cited for Recurrent Glioblastoma (CME/CE)
- Boosting Boron’s Expanding Use In Medicine
- Lipid Involved With Gene Regulation Uncovered
- Unlicensed Intravenous Form Of Relenza Helped Save Life Of Swine-Flu Infected Woman Who Had Just Had Chemotherapy
- Anticancer Compound Found In American Mayapple
Random Posts
- Monkey Study Finds Reducing Calories Thwarts Aging, Disease
- Scientists Are Reolysin The Power Of Live Biologics To Fight Cancer In Two Recent Studies
- HPA Advice On The Use Of Sunbeds
- Denosumab a Winner in Phase III Osteoporosis Trials (CME/CE, with audio)
- CombinatoRx Oncology Programs Demonstrate Synergistic Anti-Cancer Activity In Multiple Myeloma And Other B-Cell Malignancies
- Sensor Biochips Could Aid In Cancer Diagnosis And Treatment
- Cellular Pathway By Which Alcohol May Promote Cancer Progression Identified By Scientists
- Endocyte Initiates Phase 1 Trial Of EC0489 For Treatment Of Refractory Or Metastatic Solid Tumors
- Loyola Receives $2 Matching Grant From Coleman Foundation
- Hear! Hear! Texas Wines Fight Cancer Growth
Prescription Cancer Drugs
Off-Label Uses Of Drugs Should Be Approved For Very Ill Patients, Opinion Piece States
Posted by: admin in Cancer Treatment, Prescription Cancer Drugs on May 06th, 2009
FDA and Congress “should protect physicians’ and patients’ right” to use FDA-approved drugs for off-label uses “and for the first time allow drugmakers to promote off-label uses that prove beneficial,” Richard Epstein, a law professor at the University of Chicago and a senior fellow at the Hoover Institution, writes in a Wall Street Journal opinion piece. He continues, “Right now these drugs provide immense lifesaving opportunities for many sick patients, particularly those threatened by cancer.”
Epstein writes, “Cancer patients are often in desperate straits” and “when existing treatments fail, patients and physicians alike can rationally conclude that they lose nothing by rolling the dice.” He continues, “Clinical trials sometimes give way to educated guesses that a drug approved for one kind of tumor might treat a second,” adding, “In many instances the result is failure.” However, “when early results from clinical trials suggest favorable results on which the FDA is unwilling to act, off-label use begins in earnest,” Epstein writes.
Epstein writes, “Any reliable information about what drugs work has the potential to save lives — but the FDA’s slow and ponderous system can’t respond in real time to new data.” He adds, “As matters now stand, no off-label use is possible for any drug that has not been certified for some particular on-label use,” which “reduces the number of drugs available on the market for off-label experimentation.”
Epstein continues, “No one thinks that unapproved cancer drugs should be freely available to patients in the over-the-counter market.” However, making drugs that pass Phase I clinical trials available for general distribution is an option. He concludes, “This may sound radical. But when lives are at stake, we should consider drastic measures” (Epstein, Wall Street Journal, 5/2).
Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation.
© 2009 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.